226
Participants
Start Date
April 16, 2007
Primary Completion Date
April 21, 2009
Study Completion Date
April 21, 2009
Live vaccinia virus vaccine
Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
MVA Smallpox Vaccine
IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
Placebo
0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
Placebo
Physiologic normal saline for injection.
University of Iowa - Vaccine Research and Education Unit, Iowa City
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore
Saint Louis University Center for Vaccine Development, St Louis
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases, Rochester
Duke Translational Medicine Institute - Clinical Vaccine Unit, Durham
Case Western Reserve University - John T. Carey Special Immunology Unit, Cleveland
University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston, Galveston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH